LYEL
insider transactionsLyell Immunopharma, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 2 different insiders made open-market purchases in the last 365 days, totalling $25.0M.
Net shares · 365d
+960.0K
976.2K buy · 16.2K sell
Net value · 365d
$24.6M
$25.0M in · $379.0K out
Sentiment · 365d
Net buying
99% buying · 1% selling
Open-market trades · 365d
16
976.2K buy · 16.2K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·J
$0
66.5K sh
-
Sell·S
Chief Medical Officer
$25.0K
2.0K sh · $12.64
Own -9%
-
Grant·A
Director
$0
9.2K sh
Own New
-
Grant·A
Director
$0
9.2K sh
Own New
-
Grant·A
Director
$0
9.2K sh
Own New
-
Grant·A
Director
$0
9.2K sh
Own New
-
Grant·A
Director
$0
9.2K sh
Own New
-
Sell·S
Lynn Seely KEY
President and CEO
$7.3K
388 sh · $18.91
Own -1%
-
Sell·S
Chief Scientific Officer
$2.5K
130 sh · $18.92
Own -1%
-
Sell·S
Chief Operating Officer
$1.7K
89 sh · $18.92
Own -0%
-
Sell·S
VP, Corporate Controller
$4.1K
217 sh · $18.91
Own -1%
-
Grant·A
Chief Fin. and Bus. Officer
$0
140.0K sh
Own New
-
Buy·P
-
Buy·P
$12.5M
488.1K sh · $25.61
Own +52%
-
Sell·S
Lynn Seely KEY
President and CEO
$174.4K
7.5K sh · $23.39
Own -9%
-
Sell·S
Chief Scientific Officer
$39.1K
1.7K sh · $23.39
Own -9%
-
Sell·S
Chief Operating Officer
$28.9K
1.2K sh · $23.39
Own -6%
-
Grant·A
Chief Medical Officer
$0
50.0K sh
Own New
-
Grant·A
General Counsel
$0
50.0K sh
Own New
-
Grant·A
Lynn Seely KEY
President and CEO
$0
155.0K sh
Own New
-
Sell·S
Lynn Seely KEY
President and CEO
$10.1K
438 sh · $23.12
Own -1%
-
Grant·A
Chief Scientific Officer
$0
50.0K sh
Own New
-
Sell·S
Chief Scientific Officer
$3.4K
147 sh · $23.12
Own -1%
-
Grant·A
Chief Operating Officer
$0
65.0K sh
Own New
-
Sell·S
Chief Operating Officer
$2.5K
109 sh · $23.12
Own -1%
-
Sell·S
VP, Corporate Controller
$5.9K
254 sh · $23.12
Own -2%
-
Grant·A
VP, Corporate Controller
$0
8.8K sh
Own +123%
-
Grant·A
Lynn Seely KEY
President and CEO
$0
20.0K sh
Own +32%
-
Grant·A
Chief Scientific Officer
$0
4.0K sh
Own +27%
-
Grant·A
Chief Operating Officer
$0
4.0K sh
Own +26%
-
Sell·S
VP, Corporate Controller
$30.3K
936 sh · $32.32
Own -12%
-
Sell·S
VP, Corporate Controller
$43.9K
1.1K sh · $38.67
Own -12%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Innovative Cellular Therapeutics Holdings Ltd | Other J | 66.5K | $0 |
| Jun 10, 2026 | David Shook | Sell S | 2.0K | $25.0K |
| Jun 10, 2026 | Elizabeth G Nabel | Grant A | 9.2K | $0 |
| Jun 10, 2026 | Sumant Ramachandra | Grant A | 9.2K | $0 |
| Jun 10, 2026 | William Jl Rieflin | Grant A | 9.2K | $0 |
| Jun 10, 2026 | Cathy Friedman | Grant A | 9.2K | $0 |
| Jun 10, 2026 | Mark Bachleda | Grant A | 9.2K | $0 |
| May 11, 2026 | Lynn Seely KEY | Sell S | 388 | $7.3K |
| May 11, 2026 | Gary K. Lee | Sell S | 130 | $2.5K |
| May 11, 2026 | Stephen J. Hill | Sell S | 89 | $1.7K |
| May 11, 2026 | Veronica Sanchez Bulis | Sell S | 217 | $4.1K |
| Mar 9, 2026 | Smital Shah | Grant A | 140.0K | $0 |
| Mar 6, 2026 | ARCH Venture Fund XIII, L.P. / ARCH Venture Partners XIII, L.P. / ARCH Venture Partners XIII, LLC / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis / Paul L Berns / Clinton Bybee | Buy P | 488.1K | $12.5M |
| Mar 6, 2026 | ARCH Venture Partners IX, LLC / ARCH Venture Partners IX, L.P. / ARCH Venture Partners IX Overage, L.P. / ARCH Venture Fund IX, L.P. / ARCH Venture Fund IX Overage, L.P. | Buy P | 488.1K | $12.5M |
| Feb 11, 2026 | Lynn Seely KEY | Sell S | 7.5K | $174.4K |
| Feb 11, 2026 | Gary K. Lee | Sell S | 1.7K | $39.1K |
| Feb 11, 2026 | Stephen J. Hill | Sell S | 1.2K | $28.9K |
| Feb 10, 2026 | David Shook | Grant A | 50.0K | $0 |
| Feb 10, 2026 | Mark A Meltz | Grant A | 50.0K | $0 |
| Feb 10, 2026 | Lynn Seely KEY | Grant A | 155.0K | $0 |
| Feb 10, 2026 | Lynn Seely KEY | Sell S | 438 | $10.1K |
| Feb 10, 2026 | Gary K. Lee | Grant A | 50.0K | $0 |
| Feb 10, 2026 | Gary K. Lee | Sell S | 147 | $3.4K |
| Feb 10, 2026 | Stephen J. Hill | Grant A | 65.0K | $0 |
| Feb 10, 2026 | Stephen J. Hill | Sell S | 109 | $2.5K |
| Feb 10, 2026 | Veronica Sanchez Bulis | Sell S | 254 | $5.9K |
| Feb 10, 2026 | Veronica Sanchez Bulis | Grant A | 8.8K | $0 |
| Feb 9, 2026 | Lynn Seely KEY | Grant A | 20.0K | $0 |
| Feb 9, 2026 | Gary K. Lee | Grant A | 4.0K | $0 |
| Feb 9, 2026 | Stephen J. Hill | Grant A | 4.0K | $0 |
| Dec 30, 2025 | Veronica Sanchez Bulis | Sell S | 936 | $30.3K |
| Dec 24, 2025 | Veronica Sanchez Bulis | Sell S | 1.1K | $43.9K |
About LYEL insider trading
This page tracks insider transactions for Lyell Immunopharma, Inc. (LYEL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.